{
    "title": "SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors.",
    "date": 2020,
    "author": "Ludivine Grzelak, a, Sarah Temmam, a, Cyril Planchais, a, Caroline Demeret, a, Christ\u00e8le Huon, Florence Guivel-Benhassine, Isabelle Staropoli, Maxime Chazal, Jeremy Dufloo, Delphine Planas, Julian Buchrieser, Maaran Michael Rajah, Remy Robinot, Fran\u00e7oise Porrot, M\u00e9lanie Albert, Kuang-Yu Chen, Bernadette Crescenzo, Flora Donati, Fran\u00e7ois Anna, Philippe Souque10, Marion Gransagne, Jacques Bellalou, Mireille Nowakowski, Marija Backovic, Lila Bouadma, Lucie Le Fevre, Quentin Le Hingrat, Diane Descamps, Annabelle Pourbaix, Yazdan Yazdanpanah, Laura Tondeur, Camille Besombes, Marie-No\u00eblle Ungeheuer, Guillaume Mellon20, Pascal Morel, Simon Rolland, Felix Rey, Sylvie Behillil, Vincent Enouf, Audrey Lemaitre, Marie-Aude Cr\u00e9ach, Stephane Petres, Nicolas Escriou, Pierre Charneau,10, Arnaud Fontanet, Bruno Hoen, Timoth\u00e9e Bruel, Marc Eloit, b, Hugo Mouquet, b, Olivier Schwartz, b, and Sylvie van der Werf, b",
    "affiliations": [
        "Immunity Unit, Department of Virology, Institut Pasteur, Paris, France; CNRS UMR 3569, Paris, France; Vaccine Research Institute, Creteil, France",
        "Universit\u00e9 de Paris, Sorbonne Paris Cit\u00e9, Paris, France",
        "Pathogen Discovery Laboratory, Department of Virology, Institut Pasteur, Paris, France",
        "Laboratory of Humoral Immunology, Department of Immunology, Institut Pasteur, INSERM U1222, Paris, France",
        "Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur CNRS UMR 3569; Universit\u00e9 de Paris, Paris, France",
        "Department of Virology, Institut Pasteur, Paris, France",
        "National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France",
        "RNA Biology of Influenza Virus, Department of Virology, Institut Pasteur, Paris, France",
        "Pasteur-TheraVectys joined unit",
        "Molecular Virology & Vaccinology Unit, Department of Virology, Institut Pasteur, Paris, France",
        "Innovation lab : Vaccines, Institut Pasteur, Paris, France",
        "Plate-Forme Technologique Production et Purification de Prot\u00e9ines Recombinantes, Institut Pasteur, Paris, France",
        "Structural Virology Unit, Department of Virology, Institut Pasteur, Paris, France; CNRS UMR 3569, Paris, France",
        "Universit\u00e9 of Paris, INSERM UMR 1137 IAME, Paris, France",
        "Medical and Infectious Diseases Intensive Care Unit, Assistance Publique-H\u00f4pitaux de Paris, Bichat-Claude Bernard University Hospital, France",
        "Department of Infectious diseases, Assistance Publique-H\u00f4pitaux de Paris, Bichat-Claude Bernard University Hospital, France",
        "Department of Virology, Assistance Publique-H\u00f4pitaux de Paris, Bichat-Claude Bernard University Hospital, France",
        "Emerging Diseases Epidemiology Unit, Department of Global Health, Institut Pasteur, Paris, France",
        "Investigation Clinique et Acc\u00e8s aux Ressources Biologiques (ICAReB) , Institut Pasteur, Paris, France 20 Unit\u00e9 Coordination du Risque Epid\u00e9mique et Biologique, AP-HP, H\u00f4pital Necker, Paris, France 21 Etablissement Fran\u00e7ais du Sang (EFS), Paris, France 22 Service de maladies infectieuses, h\u00f4pital universitaire Cavale Blanche, Brest, France",
        "CIC 1417, CIC de vaccinologie Cochin-Pasteur, AP-HP, H\u00f4pital Cochin, Paris, France",
        "Direction alerte et crises, r\u00e9serve sanitaire, Sant\u00e9 publique France, Saint-Maurice, France 24 Centre d\u2019\u00e9pid\u00e9miologie et de sant\u00e9 publique des arm\u00e9es, Marseille 25 PACRI Unit, Conservatoire National des Arts et M\u00e9tiers, Paris, France 26 Direction de la recherche m\u00e9dicale, Institut Pasteur, Paris, France 27 National Veterinary School of Alfort, Maisons-Alfort, France a: co-first authors b: co-last authors (alphabetical order) *corresponding authors:"
    ],
    "identifiers": {
        "arxiv": null,
        "doi": "10.1101/2020.04.21.20068858",
        "isbn": null,
        "doc_id": null,
        "url": "http://medrxiv.org/cgi/content/short/2020.04.21.20068858.pdf"
    },
    "abstract": "It is of paramount importance to evaluate the prevalence of both asymptomatic and symptomatic cases of SARS-CoV-2 infection and their antibody response profile. Here, we performed a pilot study to assess the levels of anti-SARS-CoV-2 antibodies in samples taken from 491 preepidemic individuals, 51 patients from H\u00f4pital Bichat (Paris), 209 pauci-symptomatic individuals in the French Oise region and 200 contemporary Oise blood donors. Two in-house ELISA assays, that recognize the full-length nucleoprotein (N) or trimeric Spike (S) ectodomain were implemented. We also developed two novel assays: the S-Flow assay, which is based on the recognition of S at the cell surface by flow-cytometry, and the LIPS assay that recognizes diverse antigens (including S1 or N Cterminal domain) by immunoprecipitation. Overall, the results obtained with the four assays were similar, with differences in sensitivity that can be attributed to the technique and the antigen in use. High antibody titers were associated with neutralisation activity, assessed using infectious SARS-CoV2 or lentiviral-S pseudotypes. In hospitalized patients, seroconversion and neutralisation occurred on 5-14 days post symptom onset, confirming previous studies. Seropositivity was detected in 29% of pauci-symptomatic individuals within 15 days post-symptoms and 3 % of blood of healthy donors collected in the area of a cluster of COVID cases. Altogether, our assays allow for a broad evaluation of SARS-CoV2 seroprevalence and antibody profiling in different population subsets.",
    "funding": [
        {
            "award-group": [
                {
                    "funding-source": "Institut Pasteur, ANRS"
                },
                {
                    "funding-source": "Vaccine Research Institute",
                    "award-id": [
                        "ANR10-LABX-77"
                    ]
                },
                {
                    "funding-source": "Labex IBEID",
                    "award-id": [
                        "ANR-10-LABX-62-IBEID",
                        "ANR-14-CE14-0029",
                        "ANR-14-CE14-0015-01"
                    ]
                },
                {
                    "funding-source": "Gilead HIV"
                },
                {
                    "funding-source": "French Ministry of Higher Education, Research"
                },
                {
                    "funding-source": "Innovation.ME"
                },
                {
                    "funding-source": "Institut Pasteur, Labex",
                    "award-id": [
                        "ANR-10-LABX-62-IBEID"
                    ]
                },
                {
                    "funding-source": "IBEID",
                    "award-id": [
                        "ANR-10-LABX-62-IBEID"
                    ]
                },
                {
                    "funding-source": "Institut Pasteur Program,",
                    "award-id": [
                        "ANR-10"
                    ]
                },
                {
                    "funding-source": "Milieu Int\u00e9rieur Program",
                    "award-id": [
                        "ANR-10-LABX-69-01"
                    ]
                },
                {
                    "funding-source": "Agence Nationale de Recherches"
                },
                {
                    "funding-source": "H\u00e9patites Virales"
                },
                {
                    "funding-source": "Institut Pasteur, CNRS"
                },
                {
                    "funding-source": "Universit\u00e9 de Paris, Sant\u00e9"
                },
                {
                    "funding-source": "Labex IBEID",
                    "award-id": [
                        "ANR-10-LABX-62-IBEID"
                    ]
                }
            ],
            "funding-statement": "OS lab is funded by Institut Pasteur, ANRS, Sidaction, the Vaccine Research Institute (ANR10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), \u201cTIMTAMDEN\u201d ANR-14-CE14-0029, \u201cCHIKV-ViroImmuno\u201d ANR-14-CE14-0015-01 and the Gilead HIV cure program. LG is supported by the French Ministry of Higher Education, Research and Innovation.ME lab is funded by Institut Pasteur, Labex IBEID (ANR-10-LABX-62-IBEID), Reacting, EU grant Recover, ANR Oh\u2019ticks. HM received core grants from the G5 Institut Pasteur Program, the Milieu Int\u00e9rieur Program (ANR-10-LABX-69-01) and INSERM. C.P. is supported by a fellowship from the Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales (ANRS). SVDW lab is funded by Institut Pasteur, CNRS, Universit\u00e9 de Paris, Sant\u00e9 publique France, Labex IBEID (ANR-10-LABX-62-IBEID), REACTing, EU grant Recover"
        }
    ]
}